Latham & Watkins Named Capital Markets Law Firm of the Year
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”
Partner
Nate Beaton advises clients on regulatory, transactional, litigation, and legislative matters involving the US Food and Drug Administration (FDA) and other regulatory authorities with jurisdiction over healthcare and biotechnology.
Nate leverages his broad understanding of the regulatory landscape and sophisticated industry knowledge to serve as a trusted advisor for:
He guides clients on complex regulatory issues, as well as legislation and rulemaking. Nate has been involved extensively in Administrative Procedure Act (APA) litigation, challenging and defending FDA actions and regulatory programs.
Nate helps clients evaluate regulatory risks and opportunities in the context of transactions in the healthcare and life sciences sectors.
A recognized thought leader, Nate frequently speaks and writes on healthcare and life sciences topics. He serves on the Food and Drug Law Journal’s editorial review board.
Nate’s recent publications and speaking engagements include:
Nate regularly counsels at all stages of the product life cycle, including on:
Nate’s recent transactional experience includes representing:
Nate’s recent litigation and investigations experience includes representing:
Chambers USA recognized the firm as a “powerhouse in the capital markets space.”
Chambers USA recognized the firm’s Mergers & Acquisitions Practice for “world class expertise when it comes to the most challenging transactions.”